Company / PP&E (Net)
Vistagen Therapeutics, Inc. PP&E (Net) History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$507.3K
FY2023
5-year range
$207.4K / $507.3K
FY2019-FY2023
Trend
+22.4%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has increased for 3 consecutive years, from $207,400 in FY2018 to $507,300 in FY2023.
Based on SEC 10-K filings.
$507,300 in FY2023 with a 5-year CAGR of +19.6%.
Improved from $367,400 to $507,300 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +19.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vistagen Therapeutics, Inc.'s pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +19.6%, indicating consistent growth.
- In FY2023, pp&e (net) increased 22.4% year-over-year.
- Lowest pp&e (net) in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | $507.3K | +22.4% |
| FY2022 | $414.3K | +12.8% |
| FY2021 | $367.4K | +77.1% |
| FY2018 | $207.4K | -27.6% |
| FY2017 | $286.5K | +58.6% |
| FY2014 | $180.7K | +142.6% |
| FY2012 | $74.5K | +0.0% |
| FY2011 | $74.5K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026